Thursday, November 12, 2026
Cancer type
Bladder and urothelial cancer, kidney cancer, prostate cancer, and germ-cell tumors. Subtype filters sit on this page.
An ASCO GU 2026 proof-of-concept series of 33 ctDNA samples from 21 patients with germ cell tumors, most of them marker-negative, reported 100% concordance between ctDNA detection and radiologic or pathologic disease status across the treatment phases assessed.
Journal of Clinical Oncology
Among 64 patients with ctDNA drawn before primary retroperitoneal lymph node dissection, an ASCO GU 2026 analysis reported sensitivity of 88% and specificity of 85% for germ cell tumor in the non-seminoma subgroup of 37 patients; seminoma specificity could not be estimated because every seminoma specimen contained tumor.
Journal of Clinical Oncology
An ASCO GU 2026 retrospective series of patients with testicular cancer who had at least one tumor-informed ctDNA result reported that, in that chart review, ctDNA was more sensitive and specific than serum tumor markers and imaging for residual disease and recurrence.
Journal of Clinical Oncology
ClinicalTrials.gov lists NCT07401316, a diagnostic study led by Indiana University with Natera, as recruiting from a June 3, 2026 start date to measure the positive predictive value of ctDNA in high-risk stage I, stage II, and stage III germ cell tumors.
ClinicalTrials.gov